INDIAN GOVERNMENT FIRMS PREPARE TO MANUFACTURE COVAXIN

HIGHLIGHTS

• Indian Government firms are preparing to manufacture Covaxin.
• Covaxin was first developed with seed strains received from the National Institute of Virology (NIV).
• Phase 3 clinical trial of Covaxin was co-funded by ICMR.
<...

SAMSUNG BIOLOGICS BUILDING NEW PLANT FOR FUTURE GROWTH ENGINES

Highlights –

• Samsung Biologics building new plant for future growth engines.
• The company will produce and manufacture biopharmaceutical products for major pharmaceutical firms.
• The new upcoming plant is said to be worth $1.4 billion.<...

CHINA’S CLOVER BIOPHARMA VACCINE PARTNERSHIP WITH GSK COMES TO AN END

• China's Clover Biopharmaceuticals said on Monday it has ended its joint venture with GlaxoSmithKline Plc. GSK.L to develop a COVID-19 vaccine using the British drug maker's adjuvant, even as early-stage trials showed good results.
• The decision marks a further upset to G...

SK BIOSCIENCE LOOKING AT AN IPO MONEYSPINNER WITH ASTRAZENECA COVID-19 VACCINE DEAL

• Ever since a deal was reached in July for SK Bioscience to manufacture AstraZeneca's COVID-19 vaccine, the SK subsidiary has already succeeded in producing the vaccine at its Andong L HOUSE vaccine center.
• While some vials of the vaccine produced have already been exported,...

SAMSUNG BIOLOGICS BROADENS HORIZONS WITH INSTALLATION BASE IN SAN FRANCISCO

• Samsung Biologics has opened its first overseas installation in San Francisco as part of the contract policy and manufacturing organization's efforts to provide an unparalleled service network to more than 2,500 life science and biotechnology firms in the city.
• Also at the ...

IPO STOCKS IN THAILAND AND SOUTH KOREA SURGE

HIGHLIGHTS

• Investors are snapping up shares in drugmaker called SK Biopharm and glove producer Sri Trang.
• The shares of both companies are have risen above their IPO prices.

Investors in Thailand and South Korea snapped up shares in ...

SK HOLDINGS SUBSIDIARY COMPANIES ARE GAINING WELL IN STOCK MARKET

Highlights –

• SK Holdings saw share price gain by nearly 3 percent.
• The gains happened so because of its biotech subsidiary company.
•  SK Pharmteco will provide Virginia-based Phlow with active pharmaceutical ingredients.

The U.S. partner SK Biopharma is given an EMA sleepiness node.

SK Biopharmaceuticals is a global pharmaceutical company that develops new medicines to support medical innovation. As part of our quest for the SK Group next-generation rising engine, SK Biopharmaceuticals started to research and the development of new drugs in 1993. The spirited rise of SK Biop...

 U.S IPO Karuna Therapeutics gives huge returns to investors

Karuna Therapeutics is a state-of-the-art clinical-stage biopharmaceutical company mainly focused on developing original therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need.

As the company performed well in November month, the early...

USMCA concessions are acknowledged by Lighthizer: 'Democrats won the House'

It's U.S. Trade Representative Robert Lighthizer admitted that the White House had to make concessions to conclude its trade agreement with the USMCA on Sunday.

"We had an election and the Democrats won the House," he said, as CBS ' Margaret Brennan asked the Democrats...

$43M raised by Clover Biopharmaceuticals in Series B Funding

Based in China, the global clinical-stage bio-tech company Clover Biopharmaceuticalsis focusing on innovative biologic therapies, sealed a US$ 43m (RMB 304m) Series B financing.

Lead by Delos Capital and Lapam Capital, along with some help by from Betta Capital, Sichuan Health Care Indu...

Phase 1 SCB-313 for Malignant Pleural Effusion Treatment tested by Clover Biopharmaceuticals in Australia

According to an announcement by an international biotechnology company in China, Clover Biopharmaceuticals, thriving to develop new biological therapies, the first-ever cancer patient suffering from malignant pleural effusions was admitted in Australia in a fully human TRAIL-Trimer fusion protein...

Australia: Clover Biopharmaceuticals tests Phase 1 study of SCB-313 for Malignant Pleural Effusion

CHENGDU, China ( November 21, 2019 ) Clover Biopharmaceuticals, an international clinical-stage biotechnology company based on the development of novel and revelatory biological therapies, announced today that the very first patient was administered in Australia for the treatment of cancer patien...

First Patient Dosed in Phase I Study of SCB-313 for MPE by Clover Biopharmaceuticals

International clinical-stage biotechnology engaged in generating new and transformative biologic treatments, Clover Biopharmaceuticals publicized today how they had dosed their first patient in a Phase I trial of SCB-313 in Australia for treating cancer patients having malignant pleural effusions...

POP1 Drug Discovery Program Advanced by Propanc Biopharma

Propanc Biopharma, Inc., a biopharmaceutical company creating new cancer therapies for patients with recurrent and metastatic cancer, today reported that the POP1 study and drug discovery program has made great progress in the creation of synthetic variants of both proenzymes, trypsinogen, and ch...

High Times: Now Weed Is the Way to Wellness

At the point when California cast a ballot to authorize recreational cannabis in November 2016, weed smokers could have been pardoned for checking the substance of their bongs. It was a turning point. As the entertainer John Mulaney commented: "This is the first occasion when I've at any...

AstraZeneca diabetes drug approved for treating heart failure risk

AstraZeneca's diabetes drug Farxiga has been approved to be used within USA as a treatment to cut back the probabilities of medical aid for a heart condition in adults with type-2 diabetes and alternative vessel risks, British drug maker same on Mon.

The approval by the U.S. Food an...